2 studies found for:    mk-2206 | "Pancreatic Cancer"
Show Display Options
Rank Status Study
1 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unresectable Pancreatic Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
2 Completed Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Fluorouracil;   Drug: Oxaliplatin;   Drug: Selumetinib

Indicates status has not been verified in more than two years